StockData
Grace Therapeutics, Inc. logo

Grace Therapeutics, Inc. (GRCE) stock

GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$1.75−0.06 (-3.31%)

Close on Nov 16, 2026Market cap $36.81MP/E –Yield –

Grace Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Grace Therapeutics

Grace Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Grace Therapeutics figures

See a number that looks wrong?